1. 5-year progression-free survival was increased in the induction chemotherapy group compared to standard chemoradiotherapy. 2. Patients in the induction ...
1. 36-month overall survival was significantly greater in the pembrolizumab-chemoradiotherapy group compared to placebo-chemoradiotherapy. 2. Grade 3 or higher adverse ...
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
